168 related articles for article (PubMed ID: 22095092)
1. CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice.
Hansen J; Lindenstrøm T; Lindberg-Levin J; Aagaard C; Andersen P; Agger EM
Cancer Immunol Immunother; 2012 Jun; 61(6):893-903. PubMed ID: 22095092
[TBL] [Abstract][Full Text] [Related]
2. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.
Korsholm KS; Hansen J; Karlsen K; Filskov J; Mikkelsen M; Lindenstrøm T; Schmidt ST; Andersen P; Christensen D
Vaccine; 2014 Jun; 32(31):3927-35. PubMed ID: 24877765
[TBL] [Abstract][Full Text] [Related]
3. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.
Varypataki EM; van der Maaden K; Bouwstra J; Ossendorp F; Jiskoot W
AAPS J; 2015 Jan; 17(1):216-26. PubMed ID: 25387996
[TBL] [Abstract][Full Text] [Related]
4. Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model.
Liu C; Chu X; Sun P; Feng X; Huang W; Liu H; Ma Y
Hum Vaccin Immunother; 2018 Apr; 14(4):931-940. PubMed ID: 29271696
[TBL] [Abstract][Full Text] [Related]
5. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes.
Zaks K; Jordan M; Guth A; Sellins K; Kedl R; Izzo A; Bosio C; Dow S
J Immunol; 2006 Jun; 176(12):7335-45. PubMed ID: 16751377
[TBL] [Abstract][Full Text] [Related]
6. Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C).
Schmidt ST; Pedersen GK; Neustrup MA; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Front Immunol; 2018; 9():898. PubMed ID: 29760705
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
8. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
[TBL] [Abstract][Full Text] [Related]
9. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
10. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
11. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
12. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
[TBL] [Abstract][Full Text] [Related]
13. Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150.
Chen S; Ou R; Tang J; Deng X; Wu Y; van Velkinburgh JC; Ni B; Xu Y
Cancer Epidemiol; 2013 Apr; 37(2):172-8. PubMed ID: 23127963
[TBL] [Abstract][Full Text] [Related]
14. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
[TBL] [Abstract][Full Text] [Related]
15. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
16. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
18. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
20. Antigen Delivery to DEC205
Silva MO; Almeida BS; Sales NS; Diniz MO; Aps LRMM; Rodrigues KB; Silva JR; Moreno ACR; Porchia BFMM; Sulczewski FB; Boscardin SB; Ferreira LCS
Int J Biol Sci; 2021; 17(11):2944-2956. PubMed ID: 34345218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]